Risk stratification is tremendously important in hypertrophic cardiomyopathy (HCM). It defines future quality of life, insurability, and the angst of dealing with possible premature mortality. In this issue of JAMA Cardiology, Lorenzini et al1 detail mortality in patients with HCM in a study of 4893 patients followed up at 7 large European HCM centers of excellence for a median of 6.2 years. They found significant increased mortality in the HCM cohort throughout the life course compared with a matched general European population. This study is important given its large size, the inclusion of data from multiple experienced HCM centers, and high-quality analysis.
Rakowski H. Determining Hypertrophic Cardiomyopathy Mortality: Gaining Wisdom From Knowledge. JAMA Cardiol. 2020;5(1):81–82. doi:10.1001/jamacardio.2019.4548
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: